TITLE

Benzyl Alcohol Lotion 5% (Ulesfia)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
November 2009
SOURCE
Internal Medicine Alert;11/29/2009, Vol. 31 Issue 22, p174
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the indications, dosage, potential advantages and disadvantages, and clinical implications of the Benzyl Alcohol Lotion, a product approved by the U.S. Food and Drug Administration (FDA) as treatment for head lice infestation.
ACCESSION #
47682942

 

Related Articles

  • January and you still have head lice! Burnside, Mimi // Clinical Advisor;Jan2015, Vol. 18 Issue 1, p98 

    No abstract available.

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Apr2011 Clinical Brief, p2 

    The article reports on the drug approvals by the U.S. Food and Drug Administration (FDA). The FDA approved Spinosad for the treatment of head lice. The FDA issued an alert on the safety of the drug dronedarone (Multaq) approved for the prevention of atrial fibrillation because it has been...

  • Drugs in the News.  // Clarendon Enterprise (TX);5/14/2009, Vol. 20 Issue 20, p5 

    The article offers information on a drug for head lice which was approved by the U.S. Food and Drug Administration.

  • New option available for treating head lice.  // Infectious Diseases in Children;Aug2009, Vol. 22 Issue 8, p46 

    The article reports on the approval by the U.S. Food and Drug Administration on Ulesfia 5% benzyl alcohol lotion as the first non-neurotoxic topical head lice prescription treatment for use in children aged 6 months and older.

  • Labeling changes suggested for lice tx.  // Dermatology Times;May96, Vol. 17 Issue 5, p4 

    Reports that the Food and Drug Administration has recommended labeling changes for childhood lice treatments containing the pesticide lindane.

  • FDA approves topical lice treatment spinosad for patients aged 4 years and older.  // Infectious Diseases in Children;Feb2011, Vol. 24 Issue 2, p5 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the topical application of spinosad for head lice treatment in patients four years old and above.

  • Review of Common Therapeutic Options in the United States for the Treatment of Pediculosis Capitis. Jones, Kimberly N.; English III, Joseph C. // Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1355 

    Numerous therapies are available in both over-the-counter and prescription formulations for the treatment of head lice infestation. We summarize treatment recommendations from published literature and from a recent meta-analysis from the Cochrane Database of Systematic Reviews that describe the...

  • What's new for head lice treatment? Bell, Edward // Infectious Diseases in Children;Oct2009, Vol. 22 Issue 10, p8 

    The article discusses the treatment approaches for head lice.

  • FDA actions.  // Clinical Cardiology Alert;Apr2011 Pharmacology, p2 

    The articles offers news briefs related to the U.S. Food and Drug Administration (FDA). A warning has been issued concerning the use of terbutaline for prevention or prolonged treatment of preterm labor in pregnant women. The FDA has approved Spinosad, a treatment for head lice. A warning...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics